基础医学与临床BasicandClinicalMedicine202343(9)sultsofaphase1studyofloncastuximabtesirineinre⁃lapsed/refractoryB⁃cellnon⁃Hodgkinlymphoma[J].Blood,2021,137:2634⁃2645.[21]AlbingerN,PfeiferR,NitscheM,etal.PrimaryCD33⁃targetingCAR⁃NKcellsforthetreatmentofacutemyeloidleukemia[J].BloodCancerJ,2022,12:61.doi:10.1038/s41408⁃022⁃00660⁃2.[22]SoldiererM,BisterA,HaistC,etal.Geneticengi⁃neeringandenrichmentofhumanNKcellsforCAR⁃en⁃hancedimmunotherapyofhematologicalmalignancies[J].FrontImmunol,2022,13:847008.doi:10.3389/fimmu.2022.847008.[23]MukhopadhyayM.MacrophagesenterCARimmunotherapy[J].NatMethods,2020,17:561.doi:10.1038/s41592⁃020⁃0862⁃4.[24]KlichinskyM,RuellaM,ShestovaO,etal.Humanchi⁃mericantigenreceptormacrophagesforcancerimmuno⁃therapy[J].NatBiotechnol,2020,38:947⁃953.[25]ZhangW,LiuL,SuH,etal.Chimericantigenreceptormacrophagetherapyforbreasttumoursmediatedbytarge⁃tingthetumourextracellularmatrix[J].BrJCancer,2019,121:837⁃845.[26]KangM,LeeSH,KwonM,etal.Nanocomplex⁃mediatedinvivoprogrammingtochimer...